Internal Medicine Alert
RSSArticles
-
Daclatasvir Tablets (Daklinza)
Daclatasvir plus sofosbuvir is the first interferon and ribavirin-free regimen for the treatment of HCV genotype 3.
-
Delay in Performing Endovascular Reperfusion Results in Worse Disability Outcomes
For every 15-minute acceleration in the time to reperfusion, 34 per 1000 patients treated will have improved disability outcomes.
-
Botulinum Toxin and Treatment of Spasticity
AbobotulinumtoxinA is effective at reducing spasticity and reducing disability in patients with upper limb spasticity due to stroke or traumatic brain injury.
-
The Mediterranean Diet Plus Extra Virgin Olive Oil May Improve or Maintain Cognitive Function in Mature Adults
In an older population, a Mediterranean diet supplemented with olive oil or nuts is associated with improved cognitive function compared with controls on a low-fat diet.
-
Sleep Patterns Predict Diabetes Risk
Work schedules that interfered with sleep increased the risk of type 2 diabetes.
-
Clinical Briefs
In this section: improving cardiovascular outcomes through early treatment of diabetes; re-thinking PTSD treatment in veterans; and a link between rosacea and cardiovascular disease.
-
Flibanserin Tablets (Addyi)
The FDA has approved the first drug for the treatment of hypoactive sexual desire disorder in women.
-
The Impact of Hypoglycemia on Renal Impairment
A retrospective cohort study evaluated renal function data of 101 patients with type 2 diabetes and a history of severe hypoglycemia compared with a matched group of individuals with type 2 diabetes with no history of hypoglycemia.
-
Efficacy and Safety of Very Early Mobilization After Onset of Acute Stroke
The higher dose, very early (within 24 hours) mobilization protocol was associated with a reduction in the odds of a favorable outcome at 3 months after stroke occurrence.
-
SPRINT: The Systolic Blood Pressure Trial or ‘How Low Do You Go?’
Designed to see if lower blood pressures reduced the risk of blood pressure-related health outcomes, the NIH ended the SPRINT trial early and issued a news release that a lower blood pressure target significantly reduces cardiovascular complications in adults age 50 and older with high blood pressure.